Evaluation of late neurologic adverse events in patients with brain metastases from non-small cell lung cancer

Anticancer Research

Volumn 27, Issue 3 B, 2007, Pages 1701-1704

  Nieder, Carsten ^a   Astner, Sabrina T ^b   Grosu, Anca Ligia ^c   Molls, Michael ^b  

^a Radiation Oncology Unit   (Norway)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Brain metastases; Chemotherapy; Neurotoxicity; Non small cell lung cancer; NSCLC; Radiotherapy

Indexed keywords

DEXAMETHASONE; GEMCITABINE; NAVELBINE; PLATINUM DERIVATIVE; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; EDEMA; FEMALE; HUMAN; INTRACRANIAL HYPERTENSION; KARNOFSKY PERFORMANCE STATUS; LUNG NON SMALL CELL CANCER; MALE; NEUROLOGIC DISEASE; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIATION DOSE; RISK ASSESSMENT;

AGED; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; FEMALE; HUMANS; KARNOFSKY PERFORMANCE STATUS; LUNG NEOPLASMS; MALE; MENTAL DISORDERS; MIDDLE AGED; RADIOTHERAPY; SURVIVAL; TREATMENT OUTCOME;

EID: 34249332429     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Carolan H, Sun AY, Bezjak A, Yi QL, Payne D, Kane G, Waldron J, Leighl N, Feld R, Burkes R, Keshavjee S and Shepherd F: Does the incidence and outcome of brain metastases in locally advanced non-small cell lung cancer justify prophylactic cranial irradiation or early detection? Lung Cancer 49: 109-115, 2005.
2. Cortes J, Rodriguez J, Aramendia JM, Salgado E, Gurpide A, Garcia-Foncillas J, Aristu JJ, Claver A, Bosch A, Lopez-Picazo JM, Martin-Algarra S, Brugarolas A and Calvo E: Front-line paclitaxel/cisplatin- based chemotherapy in brain metastases from non-small-cell lung cancer. Oncology 64: 28-35, 2003.
3. Robinet G, Thomas P, Breton JL, Lena H, Gouva S, Dabouis G, Bennouna J, Souquet PJ, Balmes P, Thiberville L, Fournel P, Quoix E, Riou R, Rebattu P, Perol M, Paillotin D and Mornex F: Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Francais de Pneumo-Cancerologie (GFPC) Protocol 95-1. Ann Oncol 12: 59-67, 2001.
4. Bernardo G, Cuzzoni Q, Strada MR, Bernardo A, Brunetti G, Jedrychowska I, Pozzi U and Palumbo R: First-line chemotherapy with vinorelbine, gemcitabine, and carboplatin in the treatment of brain metastases from non-small cell lung cancer: a phase II study. Cancer Invest 20: 293-302, 2002.
5. Franciosi V, Cocconi G, Michiara M, Di Constanzo F, Fosser V, Tonato M, Carlini P, Boni C and Di Sarra S: Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung cancer, or malignant melanoma: a prospective study. Cancer 85: 1599-1605, 1999.
6. Guerrieri M, Wong K, Ryan G, Millward M, Quong G and Ball DL: A randomised phase III study of palliative radiation with concomitant carboplatin for brain metastases from nonsmall cell carcinoma of the lung. Lung Cancer 46: 107-111, 2004.
7. Antoniou D, Kyprianou K, Stathopoulos GP, Skarleas C, Kolitsi G, Veslemes M, Dimitroulis J, Giamboudakis P, Marosis K, Armenaki O, Papageorgiou C and Katis C: Response to radiotherapy in brain metastases and survival of patients with non-small cell lung cancer. Oncol Rep 14: 733-736, 2005.
8. Khuntia D, Brown P, Li J and Mehta MP: Whole-brain radiotherapy in the management of brain metastasis. J Clin Oncol 24: 1295-1304, 2006.
9. Nieder C, Schwerdtfeger K, Steudel WI and Schnabel K: Patterns of relapse and late toxicity after resection and whole-brain radiotherapy for solitary brain metastases. Strahlenther Onkol 174: 275-278, 1998.
10. Nieder C, Leicht A, Motaref B, Nestle U, Niewald M and Schnabel K: Late radiation toxicity after whole brain radiotherapy: the influence of antiepileptic drugs. Am J Clin Oncol 22: 573-579, 1999.
11. Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, McKenna WG and Byhardt R: Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37: 745-751, 1997.
12. Klein M, Heimans JJ, Aaronson NK, van der Ploeg HM, Grit J, Muller M, Postma TJ, Mooij JJ, Boerman RH, Beute GN, Ossenkoppele GJ, van Imhoff GW and Dekker AW, Jolles J, Slotman BJ, Struikmans H and Taphoorn MJ: Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 360: 1361-1368, 2002.
13. Kaplan EW and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958.
14. Common terminology criteria for adverse events v3.0 (CTCAE). Available online under http://ctep.cancer.gov/forms/CTCAEv3.pdf
15. Kocher M, Eich HT, Semrau R, Guner SA and Muller RP: Phase I/II trial of simultaneous whole-brain irradiation and dose-escalating topotecan for brain metastases. Strahlenther Onkol 181: 20-25, 2005.
16. Antonadou D, Paraskevaidis M, Sarris G, Coliarakis N, Economou I, Karageorgis P and Throuvalas N: Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol 20: 3644-3650, 2002.
17. Christodoulou C, Bafaloukos D, Kosmidis P, Samantas E, Bamias A, Papakostas P, Karabelis A, Bacoyiannis C, Skarlos DV; Hellenic Cooperative Oncology Group: Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. Ann Oncol 12: 249-254, 2001.
18. Kim DY, Lee KW, Yun T, Kim DW, Kim TY, Heo DS, Bang YJ and Kim NK: Efficacy of platinum-based chemotherapy after cranial radiation in patients with brain metastasis from non-small cell lung cancer. Oncol Rep 14: 207-211, 2005.
19. Penitzka S, Steinvorth S, Sehlleier S, Fuss M, Wannenmacher M and Wenz F: Assessment of cognitive function after preventive and therapeutic whole brain irradiation using neuropsychological testing. Strahlenther Onkol 178: 252-258, 2002 [in German].
20. Meyers CA, Smith JA, Bezjak A, Mehta MP, Liebmann J, Illidge T, Kunkler I, Caudrelier JM, Eisenberg PD, Meerwaldt J, Siemers R, Carrie C, Gaspar LE, Curran W, Phan SC, Miller RA and Renschier MF: Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol 22: 157-165, 2004.
21. Taphoorn MJ and Klein M: Cognitive deficits in adult patients with brain tumours. Lancet Neurol 3: 159-168, 2004.
22. Monje ML and Palmer T: Radiation injury and neurogenesis. Curr Opin Neurol 16: 129-134, 2003.
23. Dietrich J, Han R, Yang Y, Mayer-Proeschel M and Noble M: CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J Biol 5: 22, 2006.
24. Andratschke NH, Nieder C, Price RE, Rivera B and Ang KK: Potential role of growth factors in diminishing radiation therapy neural tissue injury. Semin Oncol 32 Suppl: S67-70, 2005.